VC
EWTX icon

VarCov Co’s Edgewise Therapeutics EWTX Stock Holding History

VarCov Co’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
+7,009
New +$242K 0.11% 272
2026
Q1 		– Sell
-10,034
Closed -$249K – 458
2025
Q4 		$249K Buy
+10,034
New +$201K 0.1% 363

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VarCov Co's EWTX Position: Q2 2026 in Review

VarCov Co opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 7,009 shares worth $285K. The stake represents 0.11% of the portfolio and ranks #272 among its holdings. This is a return to the name: VarCov Co previously reported a position in EWTX as recently as Q4 2025.

VarCov Co first reported a position in EWTX in Q4 2025 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • VarCov Co held 7,009 shares of Edgewise Therapeutics worth $285K as of Q2 2026.
  • Edgewise Therapeutics was a new VarCov Co position in Q2 2026.
  • Edgewise Therapeutics made up 0.11% of VarCov Co's portfolio in Q2 2026, its #272 holding.
  • VarCov Co first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.